BeOne Medicines Ltd. American Depositary Shares (ONC)
Stock · NASDAQ · Health Care
$366.79as of 8/28/2026
Price chart
Open in TradingViewActive signals
RSI Negative Divergence32.2%
High Beta22.0%
Support level
$300.61
Industry
Biotechnology: Pharmaceutical Preparations
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 12,000
- Website
- beonemedicines.com/
Fundamentals
- 1-day range
- $371.05$379.17
- Market cap
- $36.67B
- P/E (trailing)
- 88.12
- P/E (forward)
- 36.65
- EPS (trailing)
- $2.07
- Dividend yield
- —
- Beta
- 1.35
- Avg. volume
- 355.0K
52-week range
$205.51$346
Next earnings: November 5, 2026 · EPS estimate $1.82confirmed
How BeOne Medicines Ltd. American Depositary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
27 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$528
+44.0%
Median
$430
+17.2%
Low
$370
+0.9%
BeOne Medicines Ltd. American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ONCBeOne Medicines Ltd. American Depositary Shares$366.79▼ 1.53%Market cap $36.67BP/E 88.12$205.51$346
- ZTSZoetis Inc. Class A Common Stock$77.36▲ 3.12%Market cap $32.39BP/E 11.54$71$156.49
- INSMInsmed Incorporated Common Stock$118.52▼ 2.36%Market cap $28.73BP/E —$90.39$212.75
- ROIVRoivant Sciences Ltd. Common Shares$34.71▼ 7.64%Market cap $25.38BP/E —$11.62$37.97
- UTHRUnited Therapeutics Corporation Common Stock$515.57▼ 2.34%Market cap $22.62BP/E 17.03$302.19$609.35
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$18.04▲ 0.06%Market cap $53.78BP/E —$4,102$6,033
- VTRSViatris Inc. Common Stock$16.34▼ 3.26%Market cap $18.97BP/E —$9.43$18.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 88.12 | $366.79 | ▼ 1.53% | $205.51$346 |
| ZTS Zoetis Inc. Class A Common Stock | $32.39B | 11.54 | $77.36 | ▲ 3.12% | $71$156.49 |
| INSM Insmed Incorporated Common Stock | $28.73B | — | $118.52 | ▼ 2.36% | $90.39$212.75 |
| ROIV Roivant Sciences Ltd. Common Shares | $25.38B | — | $34.71 | ▼ 7.64% | $11.62$37.97 |
| UTHR United Therapeutics Corporation Common Stock | $22.62B | 17.03 | $515.57 | ▼ 2.34% | $302.19$609.35 |
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $18.04 | ▲ 0.06% | $4,102$6,033 |
| VTRS Viatris Inc. Common Stock | $18.97B | — | $16.34 | ▼ 3.26% | $9.43$18.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimensbenzinga · 8/25/2026
- Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech NewsSeekingAlpha · 8/10/2026
- BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations Using Select Clinical-Stage Oncology Assets From BeOne With Any Of Revolution’s Four Clinical RAS(ON) InhibitorsBenzinga · 8/10/2026
- TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454Benzinga · 8/6/2026
- RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450Benzinga · 8/6/2026
- Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418Benzinga · 8/6/2026
- Aaron Rosenberg Implements A Sell Strategy: Offloads $361K In BeOne Medicines StockBenzinga · 8/6/2026
- Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430Benzinga · 8/6/2026
- Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405Benzinga · 8/6/2026
Insider Activity
Insider Actions →Acquired
1.7K
Disposed
528.8K
- Aaron Rosenberg · August 3, 2026 · Sale1.2K @ $312.72
- Chan Henry Lee · July 30, 2026 · Sale1.0K @ $323.69
- Chan Henry Lee · July 22, 2026 · Option Exercise6.4K
- Chan Henry Lee · July 22, 2026 · Option Exercise8.6K
- Chan Henry Lee · July 22, 2026 · Option Exercise6.7K
- Chan Henry Lee · July 22, 2026 · Sale1.7K @ $325
- Chan Henry Lee · July 22, 2026 · Option Exercise490 @ $159.03
- Chan Henry Lee · July 22, 2026 · Option Exercise665 @ $213.32
- Chan Henry Lee · July 22, 2026 · Option Exercise514 @ $194.47
- John Oyler · July 21, 2026 · Sale2.3K @ $320.06
- John Oyler · July 21, 2026 · Sale15.8K @ $319.29
- John Oyler · July 21, 2026 · Sale7.8K @ $318.41
- John Oyler · July 21, 2026 · Sale20.0K @ $316.91
- John Oyler · July 21, 2026 · Sale15.4K @ $316.26
- John Oyler · July 20, 2026 · Option Exercise441.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.00M
- Total value held
- $2.53M
- Institutional holders
- 56
Top holders this quarter
- Unknown8.80M
- Unknown4.98M
- Unknown4.16M
- Unknown3.69M
- Unknown1.62M
- Unknown1.05M
- Unknown1.03M
- Unknown862.6K
- Unknown715.8K
- Unknown657.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 29, 2026
BeOne Medicines gains FDA approval for TEVIMBRA in gastric cancer. BeOne Medicines announced that the U.S. FDA has approved a TEVIMBRA-based regimen for first-line treatment of HER2-positive gastric, esophageal, and gastroesophageal junction adenocarcinoma. This expands the use of TEVIMBRA into an earlier line of therapy in a specific patient group. Separately, Jazz Pharmaceuticals also received FDA approval for two advanced gastric cancer regimens, which means the company is entering a space that now has additional approved competitors. The stock has been active, recently trading above its 50-day and 200-day moving averages, with an RSI in the mid-60s and support near $300.